This study investigates how using a combination of Ginkgo leaf extract, Dipyridamole injection, and antiplatelet therapy affects patients suffering from ST-segment elevation myocardial infarction (STEMI) after undergoing percutaneous coronary intervention (PCI)

Effect of ginkgo damo injection in combination with antiplatelet therapy on the treatment of STEMI patients after PCI

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN15796398

Enrollment

220

Registered

2024-04-07

Start date

2021-03-01

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) Circulatory System

Interventions

A total of 220 patients who underwent PCI following acute ST-segment elevation myocardial infarction at the Affiliated Hospital of Weifang Medical University were included in this study. Patients were

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. It meets the diagnostic criteria of acute ST-segment elevation myocardial infarction in the Guidelines for Diagnosis and Treatment of acute ST-Segment Pickup Myocardial Infarction 2. The patient underwent emergency PCI treatment within 12 hours of onset; 3. Age =17 years old; 4. Complete clinical data. 5. The knowledge and consent of all participants in the study.

Exclusion criteria

Exclusion criteria: 1. severe congenital heart disease; 2. Patients with severe liver and kidney dysfunction and malignant tumors; 3. Major surgery or trauma, cerebrovascular disease within 6 months; 4. People with cognitive or mental disorders.

Design outcomes

Primary

Measure	Time frame
Cardiac function index: For the examination of cardiac function index, the cardiac output (CO) and cardiac index (cardiac index) were measured by color Doppler ultrasound (Minrui DC-N2S) before and after treatment in the two groups. CI, left ventricular ejection fraction (LVEF) and other cardiac function indicators.	—

Secondary

Measure	Time frame
1. Bleeding risk: According to Bleeding Academic Research Consortium (BARC) bleeding classification criteria ,the number of cases of type 3 or type 5 bleeding during hospitalization and 30 days after discharge will be counted. 2. Embolization risk: thrombolysis in myocardial infarction (TIMI) blood flow rating and TIMI myocardial perfusion grade (TMPG) :TIMI blood flow grading and myocardial perfusion grading (TMPG) will be compared between the two groups before and after treatment. 3. Major adverse cardiac events (MACE) :Patients will follow up 30 days after hospitalization and discharge and MACE will be recorded, including cardiac death, myocardial infarction, recurrent angina pectoris, and revascularization.	—

Measure

Time frame

1. Bleeding risk: According to Bleeding Academic Research Consortium (BARC) bleeding classification criteria ,the number of cases of type 3 or type 5 bleeding during hospitalization and 30 days after discharge will be counted. 2. Embolization risk: thrombolysis in myocardial infarction (TIMI) blood flow rating and TIMI myocardial perfusion grade (TMPG) :TIMI blood flow grading and myocardial perfusion grading (TMPG) will be compared between the two groups before and after treatment. 3. Major adverse cardiac events (MACE) :Patients will follow up 30 days after hospitalization and discharge and MACE will be recorded, including cardiac death, myocardial infarction, recurrent angina pectoris, and revascularization.

—

Countries

China

Contacts

Public ContactYi Li

ly20141006@163.com+86 180 0536 9907

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026